Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma
We analyzed the impact of the diagnosis-to-treatment interval (DTI) on survival in patients with CD5-positive diffuse large B-cell lymphoma (CD5 + DLBCL), using a data set of newly diagnosed patients. Among the 336 eligible patients, 247 (74%) received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), and 89 (26%) were treated with dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The median DTI was 18 days (range 0–118). The short DTI (≤ 14 days) group included 135 patients (40%), and the long DTI (> 14 days) group included 201 patients (60%). Compared with the long DTI group, the short DTI group had more aggressive disease characteristics. Both the progression-free survival (PFS) (P = 0.01) and the overall survival (OS) (P < 0.01) were significantly inferior in the short DTI group compared with those in the long DTI group. Among 89 patients who received DA-EPOCH-R, no significant differences in PFS (P = 0.92) or OS (P = 0.86) were observed between the two groups. Multivariate analysis revealed that no DA-EPOCH-R was a risk factor for PFS in the short DTI group (P = 0.06). A short DTI was a negative prognostic factor in our CD5 + DLBCL cohort. DA-EPOCH-R could be considered a potential treatment option for patients with a short DTI.
Authors
- Kana Miyazaki (ORCID: https://orcid.org/0000-0001-6547-3181)
- Eiju Negoro (ORCID: https://orcid.org/0000-0003-2010-9567)
- Koji Izutsu (ORCID: https://orcid.org/0000-0001-9129-8057)
- Yuma Nato (ORCID: https://orcid.org/0000-0001-7613-4556)
- Kazutaka Sunami (ORCID: https://orcid.org/0000-0002-8229-7439)
- Motoko Yamaguchi (ORCID: https://orcid.org/0000-0002-7094-6489)
- Junji Hiraga (ORCID: https://orcid.org/0000-0002-1845-4786)
- Momoko Nishikori (ORCID: https://orcid.org/0000-0003-4171-2162)
- Taro Masunari (ORCID: https://orcid.org/0000-0002-9952-022X)
- Ilseung Choi (ORCID: https://orcid.org/0000-0002-8920-7045)
- Nobuyuki Takayama (ORCID: https://orcid.org/0000-0001-9418-9657)
- Yuri Miyazawa (ORCID: https://orcid.org/0000-0002-9857-0647)
- Satsuki Murakami
- Kohtaro Toyama
- Koji Kato
- Hiroyuki Takahashi
- Masahiro Yoshida
- Tohru Murayama
- Takahiro Okada
- Isao Tawara
- Naoto Tomita
- Yuto Kaneda
- Ritsuro Suzuki
- Naoko Asano
- Naoki Takahashi
- Jun Takizawa
- Dai Maruyama
- Koichi Ohshima
- Shuji Momose
Institutions
- Kurume University (JP)
- University of Fukui (JP)
- Kyushu University (JP)
- St. Marianna University School of Medicine (JP)
- Aichi Medical University (JP)
- Gunma University (JP)
- Shimane University (JP)
- Mie University (JP)
- Kyorin University (JP)
- Kyoto University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Nagano Prefectural Suzaka Hospital (JP)
- Osaka City General Hospital (JP)
- Gifu University Hospital (JP)
- Chugoku Central Hospital (JP)
- Toyota Kosei Hospital (JP)
- Okayama Medical Center (JP)
- Tokyo National Hospital (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Japanese Foundation For Cancer Research (JP)
- Kanagawa Cancer Center
- Niigata University (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Annals of Hematology
- Published
- 2026-04-25
- DOI
- https://doi.org/10.1007/s00277-026-07021-0
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mie University
- Kanazawa Medical University
- Shimane University
- University of Fukui
- Fujita Health University
- Nagoya City University
- Saitama Medical University
- Japan Society for the Promotion of Science